Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Am J Physiol Endocrinol Metab 283:E1173E1177 Wynne K, Park AJ, Small CJ et al (2005) Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial
Statistical analyses To describe the characteristics of patients in the cohort study, mean and standard deviation (SD) were presented for continuous data, and number ( n ) and percentage (%) were presented for categorical covariates
Available: Accessed 10 Feb 2026 Vahabi H, Wu H, Saeb M, Koo J, S
Gi tham kho: 760.000 VN 900.000 VN
In the DURATION-8 trial, dapagliflozin as monotherapy and in combination with EX-QW showed trends favoring improvements in LFC, glucose and lipid metabolism, and liver fibrosis scores at the end of the study, but no significant statistical differences were observed
US$ 29.60
US$ 20.86
US$ 25.63
US$ 27.27
US$ 20.94
US$ 29.33
US$ 24.65
US$ 21.89
